Morquio A Registry Study (MARS)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS6835
• Study ID:
  49863
• Official title and acronym:
  Morquio A Registry Study (MARS)
• DARWIN EU® study:
  No
• Study countries:
  Australia

  Austria

  Belgium

  Canada

  Czechia

  Denmark

  France

  Ireland

  Italy

  Malaysia

  Netherlands

  Poland

  Portugal

  Puerto Rico

  Taiwan

  United Kingdom

  United States
• Study description:
  A multicenter, multinational, observational Morquio A Registry Study (MARS) will be established to characterize and describe the Mucopolysaccharidosis IV type A (MPS IVA) population as a whole, including the heterogeneity, progression, and natural history of MPS IVA and to track the clinical outcomes of patients with MPS IVA treated with Vimizim®. The Registry will enroll and collect data on patients over a period of at least 8 years from the time of the first marketing approval globally and data on individual patients will continue to be collected for at least 2 years from the time the last patient was enrolled or until the Registry is terminated. It is not required that patients receive Vimizim to be eligible to participate in this Registry, however, they must have confirmed diagnosis of MPS IVA. Patients currently participating in a BMN 110 (elosulfase alfa) clinical trial will not meet inclusion criteria, but will be able to enroll after withdrawal from the clinical trial. The Registry will collect medical history, clinical, and safety assessments at least every six months or as indicated in the Recommended Schedule of Events, for up to 10 years. In addition this Registry will collect additional data on patients who have completed the MOR-005 and MOR-007 clinical trials. The MOR-005 and MOR-007 clinical trial patients will be enrolled into the appropriate Registry Substudy for a minimum of 5 years from the time of the patient's enrollment in the MOR-005 or MOR-007 clinical study. After the 5-year period, these patients should remain in MARS until the Registry is complete. Relevant retrospective data may also be collected. Registry data collected using a validated web-based application will be analyzed as per the Registry’s statistical analysis plan (SAP) and reported annually. The MARS will provide the necessary data to further characterize the spectrum of clinical signs and symptoms of the disease, and to further characterize the safety profile of Vimizim.
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Planned:28/04/2014

Actual:28/04/2014

Study start date

Planned:30/09/2014

Actual:27/09/2014

Data analysis start date

Actual:13/02/2015

Date of interim report, if expected

Planned:30/06/2022

Actual:22/06/2022

Date of final study report

Planned:31/03/2025

Actual:20/03/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

BioMarin International Limited

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 1 (imposed as condition of marketing authorisation)